


See **BRAF V600E+**, Think **RAFINLAR® + MEQSEL™**

Across multiple **BRAF V600E+** solid tumour types, RAFINLAR® (dabrafenib) + MEQSEL™ (trametinib) are recommended as a **targeted therapy combination option for advanced disease** by the NCCN Guidelines.^{3-16#}




Scan QR codes to access full prescribing information



RAF/BNR/2025-JUL/FA-11458694-1

Tumour types above do not reflect all that were included in studies of Rafinlar® Meqsel™.
*NCCN makes no warranties of any kind whatsoever regarding their content, use or application or disclaims any responsibility for their application or use in any way.
#Recommendations are for certain patients with BRAF V600E+ solid tumours. Please see individual NCCN Guidelines for detailed information.

References: 1. Rafinlar® (dabrafenib), Malaysia Packaging Insert PI RD 16 Nov 22; APPR 3 Oct 24. 2. Meqsel™ (trametinib), Malaysia Packaging Insert PI RD 16 Nov 22; APPR 3 Oct 24. 3. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Ampullary Adenocarcinoma V.2.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed May 5, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. 4. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Biliary Tract Cancers V.1.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed May 5, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. 5. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers V.5.2024. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed May 5, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. 6. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Esophageal and Esophagogastric Junction Cancers V.3.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed May 5, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. 7. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Gastric Cancer V.2.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed May 5, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. 8. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Gastrointestinal Stromal Tumors V.1.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed May 5, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. 9. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Head and Neck Cancers V.2.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed May 5, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. 10. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Melanoma: Cutaneous V.2.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed May 5, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. 11. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Neuroendocrine and Adrenal Tumors V.1.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed May 5, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. 12. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.2.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed May 5, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. 13. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer V.1.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed May 5, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. 14. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Pancreatic Adenocarcinoma V.2.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed May 5, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. 15. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Pediatric Central Nervous System Cancers V.2.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed May 5, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. 16. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Thyroid Carcinoma V.1.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed May 5, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org.



KRYXANA® has the highest
ribociclib
**recommendation from NCCN and
ESMO-MCBS for 1L treatment of
HR+/HER2- aBC¹⁻⁵**

NCCN Guidelines

KRYXANA® is the only **Category 1*** rated CDK4/6i in combination with both AI and fulvestrant for patients with HR+/HER2- aBC¹

- In phase 3 randomised controlled trials, KRYXANA® + endocrine therapy has shown **OS benefit in the 1L setting¹**

* Based upon high-level evidence (> 1 randomised phase III trials or high quality, robust meta-analysis), there is uniform NCCN consensus (> 85% support of the Panel) that intervention is appropriate.¹

ESMO-MCBS

KRYXANA® achieves the **highest ESMO MCBS score** among CDK4/6 inhibitors in the first-line setting²⁻⁵

Indications⁶

KRYXANA® is indicated for the treatment of adult patients with HR+/HER2- advanced or metastatic breast cancer in combination with:

- An aromatase inhibitor as initial endocrine-based therapy in pre / perimenopausal or postmenopausal women or in men; or
- Fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in postmenopausal women or in men.

1L, first line; aBC, advanced breast cancer; AI, aromatase inhibitor; ESMO, European Society for Medical Oncology; MCBS, Magnitude of Clinical Benefit Scale; CDK4/6i, cyclin-dependent kinases 4/6 inhibitor; HER2-, human epidermal growth factor receptor 2 negative; HR+, hormone receptor positive. NCCN, National Comprehensive Cancer Network. OS, overall survival.
References: 1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer Version 4.2025. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Available at: <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419>. Accessed May 2025. 2. ESMO MCBS scorecard 158.1. European Society for Medical Oncology. Accessed May 2025. <https://www.esmo.org/guidelines/esmo-mcbs-for-solid-tumours/esmo-mcbs-scorecards?scorecard=158-1>. 3. ESMO MCBS scorecard 9.1. <https://www.esmo.org/guidelines/esmo-mcbs-for-solid-tumours/esmo-mcbs-scorecards?scorecard=9-1>. 4. ESMO MCBS scorecard 159.1. European Society for Medical Oncology. Accessed May 2025. <https://www.esmo.org/guidelines/esmo-mcbs-for-solid-tumours/esmo-mcbs-scorecards?scorecard=159-1>. 5. ESMO MCBS scorecard 7.1. European Society for Medical Oncology. Accessed May 2025. <https://www.esmo.org/guidelines/esmo-mcbs-for-solid-tumours/esmo-mcbs-scorecards?scorecard=7-1>. 6. KRYXANA® (ribociclib) Malaysia PI RD 22 Jan 24; APPR 26 May 25.

For Healthcare Professionals only



Novartis Corporation (Malaysia) Sdn Bhd (197101000541)
Level 18, Imazium, No. 8, Jalan SS21/37 Damansara Uptown,
47400 Petaling Jaya, Selangor, Malaysia.
Tel: +603-7682 7777 Fax: +603-7682 7000 www.novartis.com.my

Scan Here To Access Product Information

KRY/BNR/2025-JUN/FA-11445754

